期刊文献+

骨髓增生异常综合征转为急性嗜酸粒细胞白血病1例并文献复习

Acute eosinophilic leukemia transformed from myelodysplastic syndrome:a case report and literature review
下载PDF
导出
摘要 目的观察急性嗜酸粒细胞白血病(AEL)的形态特征、遗传特征、免疫表型及分子标记特征以提高对AEL的认识。方法对我院收治的1例难治性血细胞减少伴多系发育异常(MDS-RCMD)转为AEL患者的病历资料进行回顾性总结并复习相关文献。结果该例MDS-RCMD患者12个月后转为AEL;骨髓原始细胞占10.4%,嗜酸粒细胞占70.8%,其中嗜酸性早、中、晚幼粒细胞占69.6%;外周血嗜酸粒细胞占13.5%;骨髓原始细胞伴有复杂染色体异常、CD34、CD117、HLD-DR、CD33、CD38、CD13等阳性表达;FI1L1/PDGFRα和ETV6/PDGFRα融合基因阴性。按AML治疗2个月后患者死亡。结论该例AEL患者FI1L1/PDGFRα和ETV6/PDGFRα基因重排阴性,伊马替尼治疗无效。 Objective To summarize and explore the morphological characteristics,genetic alterations,immunophenotype and characteristics of molecular marker of acute eosinophilic leukemia( AEL),and improve the awareness for AEL. Methods A case of refractory hematopoietic dysplasia( MDS-RCMD) transformed to AEL in our hospital was retrospectively reviewed. Results The MDS-RCMD patient transformed to AEL in 12 months after diagnosis. In his special bone marrow 10. 4% was blasts,while 70. 8% of bone marrow cells were eosinophils including 69. 3% of promyelocyte,myelocyte and metamyelocyte. Eosinophils accounted for 13. 5% in his peripheral blood. The blasts in bone marrow expressed CD34,CD117,HLA-DR,CD33,CD38 and CD13,and accompanied by complex chromosomal abnormalities. FI1 L1/PDGFRα and ETV6/PDGFRβ fusion gene were negative. The patient died two months later following treating with AML regimen. Conclusion The AEL patient with negative FI1 L1/PDGFRα and ETV6/PDGFRβ gene rearrangement,imatinib treatment is ineffectual.
作者 马金龙 陈宝安 葛峥 丁家华 高冲 MA Jinlong;CHEN Bao'an;GE Zheng;DING Jiahua;GAO Chong(Department of Hematology, Institute of Myelodysplastic Syndrome, Zhongda Hospital, Southeast University, Nanjing 210009, Jiangsu , China)
出处 《临床检验杂志》 CAS CSCD 2018年第3期235-238,共4页 Chinese Journal of Clinical Laboratory Science
基金 国家自然科学基金面上项目(81270613) 江苏省医学重点人才项目(RC2011077)
关键词 骨髓增生异常综合征 急性嗜酸粒细胞白血病 预后 myelodysplastic syndrome acute eosinophilic leukemia prognosis
  • 相关文献

参考文献3

二级参考文献46

  • 1杨天楹 张之南.嗜酸粒细胞白血病.血液病诊断及疗效标准(2版)[M].北京:科学出版社,1998.204.
  • 2Wang H, Wartg XQ, Xu XP, et al. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Leuk Res, 2010 ; 34 (5) :598 - 604.
  • 3Grosjean-Raillard J, Adds L, Boehrer S, et al. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis, 2008; 13(9) :1148 -1161.
  • 4Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood, 2009 ; 114 ( 16 ) : 3448 - 3458.
  • 5Kotsianidis I, Bazdiara I, Anastasiades A, et al. In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors. Acta Haematol, 2008 ; 120( 1 ) :51 -56.
  • 6Gondek LP, Tiu R, O'Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood, 2008; 111(3) : 1534 -1542.
  • 7Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer, 2009; 115(24):5746-5751.
  • 8Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood, 2009; 113(6): 1315-1325.
  • 9Benetatos L, Hatzimichael E, Dasoula A, et al. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute rnyeloid leukemia and myelodysplastic syndromes. Leuk Res, 2010; 34 (2) :148 -153.
  • 10Mahmud M, Stebbing J. Epigenetic modifications in AML and MDS. Leuk Res, 2010; 34(2) :139 -140.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部